PDCD1 and breast carcinoma: Nevertheless, preclinical tests using transgenic Her2 murine models of breast cancer have given promising results: Addition of a PD-1 inhibitor boosted Her2-specific CAR T-cells function and proliferation, with enhanced regression, compared to CAR T-cell administration alone (65).